Compare equivalent settings
EMA information for Mounjaro covers defined indications for type 2 diabetes and weight management. Tirzepatide acts on GIP and GLP-1 receptors, while semaglutide is a GLP-1 receptor agonist. This mechanism alone does not select a treatment. Assessment includes your circumstances, tolerability and follow-up arrangements.
Direct comparisons are more informative
SURMOUNT-5, published in 2025, compared these treatments in adults with obesity without diabetes. Tirzepatide produced greater average weight reduction at 72 weeks. That answers a particular question within this trial. It does not prove that everyone will achieve the same result or that one medicine is invariably their best choice. The trial was open-label; read its funding and protocol details in the publication.
Avoid importing a commercial ranking
Comparing medicines is not ranking fat-burning supplements. We offer no purchase link or promotional code for these medicines. Ask the clinician to explain the intended benefit, alternatives and reasons for the choice. If you saw a number on social media, record the study name instead of only saving the chart’s longest bar.
EXAMPLE / HOW TO USE IT
A reading framework
Population: with or without diabetes? Comparison: direct or two separate trials? Duration: the same? Treatments: which presentations were studied? Outcomes: benefits and adverse effects? These five questions help identify comparisons that mix different settings.
Read the figure text
Compare equivalent settings: EMA information for Mounjaro covers defined indications for type 2 diabetes and weight management. · Direct comparisons are more informative: SURMOUNT-5, published in 2025, compared these treatments in adults with obesity without diabetes. · Avoid importing a commercial ranking: Comparing medicines is not ranking fat-burning supplements.
Keep this checklist
- Identify the substances.
- Look for a direct comparison.
- Read population, duration and limitations.
- Discuss the choice within your care pathway.
Sources and limitations
- EMA — Mounjaro indications and medicine information
- Aronne et al. — SURMOUNT-5 randomised comparison, NEJM, 2025
References consulted for this edition. Studies and documents retain their actual years. Educational examples and documentary procedures, not personal product trials.
